...mos. [92% (range 66-114; p<0.001), 95% (77-115; p<0.001), and 82% (47-113; p<0.001) of baseline, respectively]. By one y...
...mos, p=0.017, HR 0.77 (0.62, 0.96); 5-yr 22.4% vs 11.1%. More pts on Arm 1 are alive without PD (p=0.008), but more died...
...mos (n=14) and ≥ 3 mos (n=12) while CISH was > 6 in 9/14 (< 3 mos) versus 1/12 (≥3 mos) (p=0.17).,The presence of an EGF...
...mos) (95% CI, 7.3-12.59) for the M- group, compared to 15.13 mos (95% CI, 9.7-20.6) for the M+ group (P=0.0047). Surviva...
...mos). Median progression-free survival (PFS): 16 mos. Median survival (MST): 26 mos. 5 year survival: 29%. MST and 5 yea...
...mOS). Study was powered to detect a significant difference with 80% probability at a significance level of 0,05 when 392...
...mos (range 5-13) after completion. All but four received from 1-5 prior treatment regimens, and 8 patients received prio...
...mos; 2 had received post-HDC radiation. 8 patients are alive and disease free 8 to 70 mos after completion of HDC (media...
...mos (median: 25 mos) after transpl, and 7 pts (14%) are alive at time of analysis, 7-75 mos (median: 40 mos) after trans...
...mos.), and one was successfully salvaged with McM with rituximab (McM+R) (NED at 51 months). One pt. treated with EPOCH+...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
